News for Altimmune, Inc. (ALT1.MX)

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (”œAltimmune” or the ”œCompa

On July 10, 2025, JMP Securities announced a revised target price for Altimmune (ALT), a biopharmaceutical company known for its innovative solutions in the hea

New York-based XCF Global, Inc. (SAFX) is up over 136 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Citizens JMP has revised its price target for Altimmune (ALT), reducing it from $25 to $15, while maintaining an

GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based th

PR NewswireNEW YORK, July 7, 2025 NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("

In a June 24, 2025, podcast, Goldman Sachs’ Christian Mueller-Glissmann and Alexandra Wilson-Elizondo examined the dynamics driving markets.

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (”œAltimmune” or the ”œCompa

PR NewswireNEW YORK, July 2, 2025 NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (”œAltimmune” or the ”œCompa

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The S&P 500 closed at a record high of 6,145.62 points on Thursday, June 26, gaining 0.88% as investors cheered progress in trade negotiations and

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

B. Riley has maintained its Buy rating for Altimmune (ALT) but is reassessing its $20 price target. This decision follows the release of results from the compan

Shares of Altimmune (ALT) experienced a significant decline following the release of results from the IMPACT trial. The company revealed encouraging topline dat

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. The Dow traded up 0.82% to 43,335.29 while the...

Altimmune's stock dropped sharply by 64% after mixed Phase 2b trial results for pemvidutide. The drug successfully met its primary endpoint, resolving M

U.S. stocks traded higher this morning, with the Dow Jones index gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of Altimmune, Inc. ALT fell sharply in today's ...